NCM
RCKT icon

Nantahala Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Nantahala Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-629,749
Closed -$4.2M – 166
2025
Q1 		$4.2M Buy
+629,749
New +$6.22M 0.17% 79

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Nantahala Capital Management's RCKT Position: Q2 2025 in Review

Nantahala Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 629,749 shares — an estimated $4.2M sold.

Nantahala Capital Management first reported a position in RCKT in Q1 2025 and held it in 1 quarter. The position peaked at $4.2M in Q1 2025. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Nantahala Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 629,749 Rocket Pharmaceuticals shares in Q2 2025, an estimated $4.2M.
  • Nantahala Capital Management first reported a position in Rocket Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Nantahala Capital Management's Rocket Pharmaceuticals position peaked at $4.2M in Q1 2025.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Nantahala Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.